 |
SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a partnership with the Society for Immunotherapy of Cancer (SITC). This collaboration will launch the "Lunit Research Program" for SITC members, granting access to Lunit SCOPE® IO for quantitative immune phenotyping and tumor microenvironment (TME) analysis from H&E whole slide images (WSIs).
Lunit and SITC collaborate to offer SITC members exclusive access to Lunit SCOPE IO for AI-driven tumor microenvironment analysis.
Through this program, Lunit and SITC will support academic and non-profit researchers who are SITC members by offering use of Lunit's AI model, Lunit SCOPE IO, at no cost. The program will enable participants to conduct advanced analyses of histologic features from H&E whole slides images, including cell identification such as Tumor-Infiltrating Lymphocytes (TILs), macrophages, endothelial cells, and more; tissue segmentation; and quantitative immune phenotyping (e.g. inflamed, excluded, and desert), providing valuable insights for biomarker discovery and immunotherapy research.
Lunit SCOPE IO is an AI solution developed to quantify histology from H&E WSIs, bridging the gap between pathology and precision oncology. Its advanced capabilities provide researchers with insights into the immune landscape of tumors, enabling the identification of biomarkers predictive of immunotherapy response. This innovative approach supports the discovery of novel treatment strategies and enhances cancer immunotherapy research.
Lunit SCOPE IO leverages advanced deep learning algorithms to provide:
- Quantitative Immune Phenotyping: Classifying the tumor microenvironment into inflamed, excluded, and desert phenotypes provides actionable insights for immunotherapy strategies.
- TIL Analysis: Identifying and quantifying Tumor-Infiltrating Lymphocytes, a key biomarker for immune response.
- Comprehensive TME Profiling: Analyzing histologic features including stromal and immune components such as fibroblasts, macrophages, and endothelial cells.
- Support for Biomarker Discovery: Enabling researchers to identify novel biomarkers and assess correlations with therapeutic outcomes in cancer immunotherapy.
Program Highlights
- Eligibility: The program is open to SITC members affiliated with academic or non-profit research institutions, holding positions such as faculty member, research scientist, or postdoctoral fellow. Applicants must demonstrate expertise in oncology, pathology, or immunology.
- Application Process: Eligible members can submit a brief study outline (1-2 pages) and the principal investigator's CV. The application period runs from February 1 to April 30, with a review process taking 2-3 months.
- Resources Provided: Participants will receive complimentary access to Lunit SCOPE IO for analysis of H&E slides, as well as optional slide scanning services at cost.
- Desired Outcomes: The program encourages peer-reviewed publications and conference presentations detailing findings from studies using Lunit SCOPE IO.
- Application Period: February 1 - April 30, 2025
- Review and Notifications: May - July 2025
- Project Start Date: Summer 2025
"For forty years, SITC has been at the forefront of driving the immuno-oncology field in an effort to positively affect patient outcomes," said Mary Dean, Executive Director of SITC. "SITC is excited to make this benefit available to its members, enabling advancement to their impactful research."
Contact Information
For inquiries about the program, please contact:
- Dr. Siraj Ali, MD, PhD
- Email: [email protected]
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,500 medical institutions across 55+ countries.
Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on X, LinkedIn, Facebook and YouTube.